Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

Hospital Clinic of Barcelona

Status and phase: Completed; Phase 4

Conditions: HIV Infections

Treatments: Drug: Combivir+Reyataz; Drug: Combivir+Kaletra

Study type: Interventional

Funder types: Other

Identifiers

NCT00385645

DATEM-PEP

Details and patient eligibility

About

The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.

Enrollment: 255 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18
• HIV exposure requiring prophylaxis under current guidelines

Exclusion criteria

• Pregnancy
• Suspected drug resistance in source case
• Contraindications to the study drugs

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)